1

Novan

Novan
Leadership team

Mr. Brian M. Johnson (Chief Commercial Officer)

Ms. Paula Brown Stafford M.P.H. (Pres, CEO & Chairwoman)

Mr. John M. Gay CPA (CFO & Corp. Sec.)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
0 - 50
Headquarters
Morrisville, North Carolina, United States
Established
2008
Company Registration
SEC CIK number: 0001467154
Revenue
5M - 20M
Traded as
NASDAQ:NOVN
Social Media
Overview
Location
Summary
Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
History

Novan was founded in 2000 by a team of scientists and entrepreneurs with a vision for creating inventive new treatments for chronic and infectious diseases.

Mission
To discover, develop and deliver novel treatments to patients with unmet medical needs.
Vision
To be a global leader in the discovery and development of innovative therapies that improve and extend people’s lives.
Key Team

Mr. Andrew J. Novak (VP of Accounting & Bus. Operations and Chief Accounting Officer)

Dr. Carri Geer Ph.D. (Sr. VP & CTO)

Mr. Cole Ikkala (Director of Investor Relations, Communications & Bus. Devel.)

Mr. Stanley Hollenbach BS, J.D. (Sr. VP of R&D)

Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D. (Chief Medical Officer)

Mr. John A. Donofrio Jr. (Exec. VP, COO & Pres of EPI Health)

Recognition and Awards
Novan has been recognized with numerous awards including the 2019 CPhI Pharma Award for Best Biotech Company.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Novan
Leadership team

Mr. Brian M. Johnson (Chief Commercial Officer)

Ms. Paula Brown Stafford M.P.H. (Pres, CEO & Chairwoman)

Mr. John M. Gay CPA (CFO & Corp. Sec.)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
0 - 50
Headquarters
Morrisville, North Carolina, United States
Established
2008
Company Registration
SEC CIK number: 0001467154
Revenue
5M - 20M
Traded as
NASDAQ:NOVN
Social Media